Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

Bristol-Myers Squibb (BMS) building

BMS cuts salesforce on revised Abilify deal

Nearly 500 jobs to go as US rights to schizophrenia blockbuster return to Otsuka

- PMLiVE

Takeda acquires US-based drug discovery company Envoy

Japanese pharma firm gains target identification technology and preclinical CNS assets

Sanofi’s Christopher Viehbacher to take the reins at EFPIA

Will serve as European pharma body's president from next June

- PMLiVE

The Empowered Patient and the Pharma Brand

With so much evolving in how healthcare is delivered, what are the implications for the pharma marketer? For a start, if you haven’t already, put away those Magic Markers…

Novartis building

EC approves extra tumour indication for Novartis’ Votubia

First drug approved in Europe for non-cancer tumours associated with TSC

- PMLiVE

India revokes Roche’s Pegasys patent after patient group challenge

Company becomes latest in big pharma to see intellectual property overturned

- PMLiVE

Xarelto uses extended in US

New FDA approval could be huge sales boost for Bayer's and J&J's anticoagulant

- PMLiVE

Chiltern promotes Aize Smink and Linda Christmas

CRO makes changes as new CEO Dr Jim Esinhart takes office

- PMLiVE

UK to amend and strengthen NHS constitution

Includes measures to involve patients in end-of-life care discussions

- PMLiVE

ABPI appoints Pfizer’s Colette Goldrick as first Northern Ireland director

Will develop relationships with key opinion leaders in region

- PMLiVE

Life through a lens: understanding patient behaviour

People’s actions and perceptions must be viewed through the lens of behavioural economics if we are to make sense of what they do, says Sarah Phillips from InCite

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links